#08 What motivates the World Orphan Drug Congress Europe 2022?
In our podcast series "Profcast - rare diseases and their therapies", Prof. Matthias P. Schönermark M.D., Ph.D. reports on the three dominant topics incentive systems, harmonization of European HTA processes, and affordability. He also conducts live interviews with Matthias Heck, director of global government affairs at Alexion Pharmaceuticals, and Adam Plich, founder and CEO of Avanzanite Bioscience.
For more information about the World Orphan Drug Congress, visit https://www.terrapinn.com/conference/world-orphan-drug-congress/index.stm
About the Profcast
Our SKC podcast series "The Profcast - rare diseases and their therapies" aims to address the special circumstances of patients with rare diseases, the associated medicine and the challenges for research, development, economics and reimbursement. For this purpose, Prof. Matthias P. Schönermark, M.D., Ph.D., managing director of SKC, speaks with patient representatives, payers, clinicians and scientists as well as industry representatives and also focuses on specific diseases. The word Profcast is a reference to professionals or professors, whom he welcomes as his guests.
The ambition behind this is to give an appropriate space to rare diseases and their treatment sine ira et studio. After all, the motto of the Rare Disease Day states it so aptly: "Rare is many". It is estimated that 4 million people in Germany and 300 million people worldwide are affected by a rare disease. In keeping with the Rare Disease Day, which traditionally takes place on the last day of February, the Profcast is published on the last day of a month.